MAP2K7 and colorectal cancer: Furthermore, Ziemke et al. verified that cotargeting MEK and CDK4/6 could be effective in treating KRAS-mutant colorectal cancers and was highly effective in all three KRAS-mutant colorectal cancer PDX models [208].